Podcasts about Eli Lilly

Inside INdiana Business Radio for the morning of June 18, 2025. Eli Lilly and Co. is looking to acquire Verve Therapeutics in a deal valued at up to $1.3 billion. Indianapolis International Airport has broke ground on a $205 million hotel that will serve as a "gateway" to the airport. Plus, Herff Jones is planning an $8 million expansion of its Indianapolis headquarters. Get the latest business news from throughout the state at InsideINdianaBusiness.com.

Hier geht's zur großen Finanzpodcast-Nacht in München: https://www.myticket.de/de/ohne-aktien-wird-schwer-tickets#10229395837004 Erfahre hier mehr über unseren Partner Scalable Capital - dem Broker mit Flatrate und Zinsen. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Politische Börsen haben kurze Beine. Solar-Aktien wie Sunrun, Enphase & First Solar brauchen Steuervorteile. Intel & Amazon streichen Jobs. SK Hynix profitiert von Mutter. Adobe leidet unter App. Softbank verkauft T-Mobile US. Eli Lilly kauft Verve Therapeutics. GTA 6 kommt… 2026. Oder auch nicht. Genau an der Frage hängt das Schicksal von Take-Two Interactive (WKN: 914508). Ein Weltmarktführer im Tech-Bereich mit legendären Marken, keinen Schulden und fast 10% Dividendenrendite. Tut Tut Baby Flitzer, Gigaset-Telefone und Kidizoom-Kameras. Das alles ist VTech (WKN: A1C3BF). Diesen Podcast vom 18.06.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

This week, BioSpace is at 50% power as Heather McKenzie and Jef Akst are off attending this year's BIO Conference in Boston. The half-team discusses this week's biggest news: the death of another patient who took Sarepta's Duchenne muscular dystrophy gene therapy Elevidys. The patient was a non-ambulatory teenager who experienced acute liver failure after receiving the gene therapy, which is the same cause of death for an Elevidys patient reported in March. Sarepta announced that it was halting treatments to non-ambulatory patients and on a media call discussed new steps in its therapeutic protocol for preventing further liver injuries.  Elsewhere, mergers and acquisitions are surging across biopharma. Eli Lilly picked up the gene editing company Verve Therapeutics for $1.3 billion, which helped bolster the gene editing space —particularly after Sarepta's report of the death. Supernus bought Sage Therapeutics for $795 million, five months after Sage rejected a smaller offer from Biogen.  BioNTech also got in on the dealmaking, buying its German rival—scientifically and in the courtroom—CureVac for about $1.25 billion. The deal seemed focused mostly on CureVac's early-stage cancer immunotherapy pipeline, but analysts were otherwise left scratching their heads on what BioNTech was getting for its money.  Last week on The Weekly the team discussed the sudden dismissal of the CDC's entire ACIP committee, and this week we have a new slate of members. The eight people replacing the 17 members that were removed last week include allies of HHS Secretary Robert F. Kennedy Jr., many of whom are vaccine skeptics who seem to share his skeptical view of vaccination in general.  

US equity futures are pointing to a lower open today. European markets have opened in the negative territory, following mixed trades in Asian markets. Global markets today are digesting Trump's decision to cut short his G7 attendance to return to Washington after warning on Truth Social for people to evacuate Tehran. BOJ left interest rates unchanged as expected. Ishiba and Trump failed to reach agreement at G7. US and Canada are aiming to strike a trade deal within a month.Companies mentioned: Verve Therapeutics, Eli Lilly, T-Mobile, Softbank

Breaking news hits Morning Trade Live with JetBlue (JBLU) cutting back flights after it reported weaker travel demand. Diane King Hall talks about the report and shares how it differs from its airline peers. She also notes the sell-off in solar stocks like First Solar (FSLR) after the Senate proposed cuts to wind and solar tax credits. Diane later discusses Eli Lilly's (LLY) $1.3 billion bid for Verve Therapeutics (VERV) and Lennar's (LEN) earnings beat.

The CEO of Cava reacts to a weaker than expect retail sales number, giving his outlook for the consumer and inflation. Then Eli Lilly's acquisition spree continues. More on their latest deal and the company's growth strategy. Plus an exclusive look at Citadel CEO Ken Griffin's advice to the firm's incoming intern class. Carl Quintanilla and Sara Eisen have it all on Money Movers.

Inside INdiana Business Radio for the afternoon of June 17, 2025. A Rose-Hulman alum gets help from current students to further develop his mobile baseball bat testing system. Plus, Eli Lilly and Co. makes another acquisition, this time worth up to $1.3 billion. Get the latest business news from throughout the state at InsideINdianaBusiness.com.

Je leest het goed. De rijkste man van de wereld heeft miljarden nodig. Geld dat 'ie gebruikt om zijn AI-imperium uit te bouwen. Het moet dé concurrent worden van OpenAI. Een bedrijf dat dan weer écht in oorlog ligt met Microsoft.We hebben het er deze aflevering over. Dan hebben we het ook over die echte oorlog. Die tussen Israël en Iran. In Iran smeken ze president Trump om een wapenstilstand in te lassen, maar daar heeft hij geen trek in. Waardoor de onzekerheid op de beurs (voor jou) nog langer aanhoudt.We ontdekten trouwens dat het ondanks die oorlog prima beleggen is in Tel Aviv. Nou ja prima. Fantastisch. Waarom dat is, je raadt het al: daarvoor moet je toch echt luisteren.Hoor je ook meer over een miljardenovername van Eli Lilly en de handelsdeal die Trump heeft gesloten met de EU. Of was het nu met het Verenigd Koninkrijk? See omnystudio.com/listener for privacy information.

Ian Bremmer, president of the Eurasia Group, joins "CBS Mornings" to break down a weekend of deep division in the U.S., as millions protested President Trump and his military parade, and deadly new strikes between Iran and Israel raised fears of a wider regional war in the Middle East. The jury in Karen Read's retrial began deliberations Friday afternoon and will continue Monday. Read is facing three charges in the 2022 death of her police officer boyfriend, John O'Keefe, including second-degree murder. Her first trial ended with a hung jury. Pharmaceutical giant Eli Lilly announced a price cut for its drug, Zepbound, for people who aren't using insurance. CBS News' Nancy Chen reports on the qualifications for the discount and what the cost reduction will be. Artificial intelligence is being used to create realistic video and audio to impersonate people, in some cases looking for love or deceiving companies looking to hire. In a 2024 study, half of the businesses surveyed said they'd experienced AI deepfake fraud. CBS News MoneyWatch correspondent Kelly O'Grady reports. In this week's "Beg-Knows America," CBS News contributor David Begnaud revisits the life-changing world of high school speech and debate, an activity that shaped his own path. He meets the inspiring young voices featured in the new documentary "SPEAK," tackling grief, identity, and advocacy with extraordinary courage. Consumer Reports' deputy editor Brian Vines joins "CBS Mornings" to share the latest sunscreen testing results, including top-rated picks and expert tips to keep you and your family safe in the sun this summer. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

The tragic death of a second non-ambulatory DMD patient treated with Sarepta's Elevidys gene therapy marks a turning point for the field and should drive all stakeholders to come together to figure out how to safely treat patients with this new modality. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the opportunity FDA, companies and patient advocates have to share data and identify a safe path forward for the gene therapy field, both in DMD and beyond.The analysts also review promising early data for amylin agonists to treat obesity from Metsera and Eli Lilly, and discuss the vision for FDA's future laid out by Commissioner Marty Makary and CBER director Vinay Prasad. This episode of BioCentury This Week was sponsored by ICON Biotech.View full story: https://www.biocentury.com/article/656214#biotech #biopharma #pharma #lifescience #obesity #FDA #DMD00:01 - Sponsor Message: ICON Biotech01:19 - Gene Therapy Safety11:55 - Amylin in Obesity18:17 - FDA's FutureTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

In this episode, Dr. Ashwin Parihar speaks with Dr. Petrice Cogswell about the radiologist's critical role in diagnosing Alzheimer's disease and how imaging advances are reshaping early detection. They also explore how innovation at scale, platform thinking, and operational alignment drive progress across complex healthcare systems. This episode is sponsored by Eli Lilly and Company.

Novo Nordisk og Eli Lilly giver deres bud på fremti­dens vægttabs­me­dicin. Kopimedicin kommer også til Europa. Teslas salg faldt tungt i Danmark i 2024. Dansk iværksætter dropper børsnotering i New York. Forsvarsaktier er braget op og er nu dyrere end tech. Demonstrationer fortsætter i L.A. og soldater sættes ind. Vært: Lasse Ladefoged (lala@borsen.dk)  

Mumbai markets are leading the global pack — but can sky-high valuations in cement and defense stocks hold? Hosted by Michelle Martin with Ryan Huang, we unpack India’s stunning 10% rally and what’s driving the bull run. JPMorgan’s bullish on beaten-down biotech: hear why Eli Lilly, Gilead, Merck, Regeneron, and Bristol Myers are back on their radar. DocuSign gets punished despite strong earnings — what’s spooking investors? Keppel DC REIT climbs back into the STI on AI-data centre bets, while Hello Kitty’s parent Sanrio outpaces Toyota. Plus, the Straits Times Index movers: CDL, Yangzijiang, and DFI Retail. See omnystudio.com/listener for privacy information.

I dagens avsnitt blir det, något oväntat, medtech på tapeten med C-RAD, Integrum och Stille. Men först ut blir det lite diverse tjöt om flertalet saker. Ett nyhetssvep och update (00:06:48) där vi pratar om Hacksaws IPO, Camurus & Eli Lilly, CFO-byte i Hellofresh, bygg- och fastighetsmarknaden och lite till. Vi övergår sedan till medtech, där Hästen kollar till C-RAD (00:35:52). Bolagen ser billigt ut, men alltid något som skaver lite i caset. Uppnår bolaget sina nya mål så är det ju verkligen inte dyrt nu. Bolaget har en stark marknadsposition men obefintligt insynsägande spökar. Gedda kollar sedan till Integrum (00:57:05). Stora ändringar i ledning och styrelse har skett. Kursen har varit volatil och kvartalen likaså. Grym produkt, höga bruttomarginaler och stor TAM kanske kan vara rätt så intressant?Sist ut blir en kik på Stille (01:25:31). Caset har blivit lite utav en darling, men Q1-rapporten var inget monster. Den långa tesen lever dock… Organisk tillväxt i ett i grunden kvalitativt bolag som kan göra en roll-upp med Linc och Impilo bakom spakarna. Vi avslutar med en Veckans volley (01:40:28) som vi alltid gör. Tack återigen till SAVR och PinPoint! Ni gör det möjligt för oss att fortsätta. Kolla in vår SAVR-portfölj på Twitter/X och Bluesky: @GottTjotAktierMaila in till: gotttjotomaktier@gmail.comFölj oss på Twitter/X och Bluesky: @GottTjotAktier, @MarkusGedda & @aktiehesten-(00:06:49) - Hacksaw(00:18:41) - Camurus(00:22:20) - Hellofresh(00:23:54) - Bygg- och fastighetsmarknaden(00:30:27) - Infracom(00:32:48) - Adtraction(00:35:52) - CRAD(00:57:05) - Integrum
(01:25:31) - Stille(01:40:28) - Veckans volleySupport this show http://supporter.acast.com/nantingomaktier. Hosted on Acast. See acast.com/privacy for more information.

In a groundbreaking development for the digital health world, Eli Lilly, one of the world's largest pharmaceutical companies, has filed lawsuits against a growing number of telehealth companies over the sale of compounded drugs Mounjaro and Zepbound, two popular GLP-1 medications. Nawa Lodin, Associate, Wilson Sonsini Goodrich & Rosati, and Lauren Petrin, Associate, Wiley Rein, discuss the background of compounding and when it is allowed under FDA regulations; the legal and regulatory issues at play in Eli Lilly's lawsuits, including issues related to the corporate practice of medicine and FDA regulations; and key compliance considerations. Watch this episode: https://www.youtube.com/watch?v=XstaVQGtY24AHLA's Health Law Daily Podcast Is Here! AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Premium members. Get all your health law news from the major media outlets on this new podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast.

EP. 215: I sat down with Brad Hart, owner of Forest Park Pharmacy in Fort Worth, to expose the shocking truth behind pharmacy benefit managers (PBMs) and how they're driving up drug prices. What I learned about vertical integration in the healthcare system, where insurers own the PBMs and the pharmacies, honestly left me furious. Brad breaks it all down, from Medicare waste to the skyrocketing cost of specialty drugs, and we talk about real solutions like compounding pharmacies and direct-to-consumer options. This is a must-listen if you've ever wondered why your medications cost so much—and who's really profiting. Topics Discussed:  What are pharmacy benefit managers (PBMs) and how do they increase drug prices? How are health insurance companies profiting from vertical integration in the pharmacy system? Why are independent and rural pharmacies struggling to stay open? What impact do PBMs have on Medicare spending and prescription drug costs? How can consumers save money on medications without relying on insurance? Sponsored By: Qualia | Go to qualialife.com/DRTYNA for up to 50% off your purchase and use code DRTYNA for an additional 15% Maui Nui Venison | Head to mauinuivenison.com/DRTYNA to secure your access now.  LMNT | Get your free Sample Pack with any LMNT purchase at drinkLMNT.com/drtyna BIOptimizers | Go to bioptimizers.com/tyna and use promo code TYNA10 to order Masszymes now and get 10% off any order Sundays | Get 40% off your first order of Sundays. Go to sundaysfordogs.com/DRTYNA and use code DRTYNA at checkout. Relax Tonic | Go to https://store.drtyna.com/products/relaxtonic and use code and use DRTYNASHOW to save 10% On This Episode We Cover:  00:00:00 - Introduction  00:04:34 - History of PBMs 00:09:02 - Insurance & Pharmacy Ties 00:12:17 - UnitedHealthcare's Role 00:15:59 - Pharmacy Kickbacks 00:18:01 - Emergency Med Access 00:23:11 - Rural Pharmacy Crisis 00:26:20 - How Insurance Works 00:30:05 - Compounding Pharmacies Explained 00:35:19 - How Pharmacies Save Money 00:37:14 - Arkansas PBM Bill 00:39:12 - Trump's Drug Pricing Executive Order 00:42:37 - Direct-to-Consumer Drugs 00:43:40 - Wegovy, Eli Lilly, & Changing Costs 00:46:27 - Medicare Waste 00:48:25 - Medicare Price Negotiation 00:49:58 - Specialty Drug Cost 00:54:18 - Brad's Pharmacy Model Further Listening:  The Fight For Affordable GLP1s & The Truth About Big Pharma | Dave Knapp  Check Out Brad:  https://www.forestparkpharmacy.com/ Instagram TikTok YouTube Disclaimer: Information provided in this podcast is for informational purposes only. This information is NOT intended as a substitute for the advice provided by your physician or other healthcare professional, or any information contained on or in any product. Do not use the information provided in this podcast for diagnosing or treating a health problem or disease, or prescribing medication or other treatment. Always speak with your physician or other healthcare professional before taking any medication or nutritional, herbal or other supplement, or using any treatment for a health problem. Information provided in this blog/podcast and the use of any products or services related to this podcast by you does not create a doctor-patient relationship between you and Dr. Tyna Moore. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent ANY disease.

"You cannot not believe in science," says Tsvetta Kaleynska. She sees biotech companies outperforming in 2025 despite a slow start to the year. Tsvetta argues investors need to understand that many companies don't just produce medicine, but also medical supplies, which contributes to profits. She sees Abivax (ABVX) as an international outperformer and expects Eli Lilly (LLY) to make a comeback in the weight loss drug market. George Tsilis highlights example options trades in Eli Lilly and Johnson & Johnson (JNJ).======== Schwab Network ========Empowering every investor and trader, every market day.Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6DSubscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Aktien hören ist gut. Aktien kaufen ist besser. Bei unserem Partner Scalable Capital geht's unbegrenzt per Trading-Flatrate oder regelmäßig per Sparplan. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen.  Baby Shark geht an Börse. BYD geht klein nach Japan. Meta geht zurück zu Palmer Luckey. Mai war geil für DAX, NASDAQ, S&P 500 und Michael O'Leary. Nur Regeneron, Eli Lilly & UnitedHealth leiden. Sonst so: GAP, Costco & Ulta mit Zahlen. Mit Evotec (WKN: 566480) konnte man sein Vermögen schonmal verhundertfachen. In den letzten Jahren hat man's eher vernichtet. Wie erklären, wie der Turnaround klappen soll. 70 Milliarden an verwaltetem Vermögen und mehr als 10% Rendite pro Jahr. Marshall Wace macht's möglich. Obwohl sich die zwei Gründer noch nie einig waren. Durch KKR (WKN: A2LQV6) kann man sogar investieren. Diesen Podcast vom 02.06.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. News stories of note for this week include a major deal signed between Eli Lilly and Rznomics in the field of RNA-editing therapies, and a potential quality-of-life breakthrough for patients with Parkinson's. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

Dr. Shalabh Gupta, founder and CEO of Unicycive Therapeutics, shares his inspiring journey from practicing medicine to leading groundbreaking innovations in kidney disease treatment. Dr. Gupta discusses his comprehensive framework for identifying and developing medical solutions, his vision for Unicycive's future, and the importance of focus and execution in medical startups. He reveals the challenges and triumphs of bringing life-changing products to market and offers profound advice for new entrepreneurs in the industry.   Guest links: https://unicycive.com/  Charity supported: Feeding America Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com.  PRODUCTION CREDITS Host: Lindsey Dinneen Editing: Marketing Wise Producer: Velentium   EPISODE TRANSCRIPT Episode 056 - Dr. Shalabh Gupta [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello, and welcome back to another episode of The Leading Difference podcast. I'm your host, Lindsey, and today I am so excited to introduce you to my guest, Dr. Shalabh Gupta. Dr. Gupta is the founder and CEO of Unicycive Therapeutics. He is a visionary in healthcare, leading groundbreaking efforts to design innovative therapies and reimagine how we approach unmet medical needs. His work goes beyond the lab as he's driving a healthcare revolution by developing innovative therapies addressing critical gaps in treatment. His perspective combines decades of experience and expertise in drug design with a deep commitment to equity in health care. Well, welcome to the show, Shalabh. I'm so excited that you're here with me today. [00:01:35] Dr. Shalabh Gupta: Thank you. Thank you for hosting me. [00:01:36] Lindsey Dinneen: Of course. I'd love if you wouldn't mind just telling us a little bit about yourself, your background, and what led you to MedTech. [00:01:45] Dr. Shalabh Gupta: By way of background, I'm a physician, trained, practiced, did my medical training in internal medicine, residency in physical medicine and rehab, research fellowship in cardiac and pulmonary rehabilitation, board certified physician, practice in New York at NYU hospital, NYU Medical Center. This is where I did my medical training for roughly decade after finishing medical school. I also have a graduate degree in finance management from NYU. While I was doing my residency training, I realized that I wanted to find a way to have a broader impact on society as well as what we were working on in learning medicine. So, I started my career working initially with a biotechnology company at the time to help them get their drug with FDA through a regulatory approval process. The beginning of the process is called IND following a investigation new drug application, IND application. I actually visited FDA on their behalf, met with FDA back in the time when everything used to be in person. Built from there onward, joined Wall Street from working as a stock analyst. So I covered biotech companies as a stock analyst, and the weekend and holidays that were available, I worked to continue to practice the medicine at NYU as an attending physician, and then joined another bank and covered pharmaceutical stocks and worked covering six of the largest pharma companies that include Pfizer, Merck, Viacom, Selling Power, Eli Lilly, Bristol Myers Squibb. From there, I moved to California. I worked for Genentech in corporate strategy. Genentech, at the time, and continues to be, one of the largest biotechnology companies. And from working at Genentech, I got my inspiration to start my own companies. So I founded two companies prior to finding starting Unicycive. All my companies are focused on aesthetic therapeutic area. Unicycive is focused on nephrology, treatment of kidney diseases, and we have two drugs in development. We have a lead drug that is pending approval from the US FDA in June of 2025 this year. And the second, I guess, finish phase 1 clinical trial in the UK. And we are in discussion with the agency to proceed with the next stage of clinical trial in the US. So that's a quick background. [00:04:14] Lindsey Dinneen: Wow. That's incredible. Thank you for sharing your story. Yeah. So let's talk about your company now. You've become CEO of this company. You're developing these products that are going to change lives. What first made you realize that there was a gap that needed to be filled in the market for this? And then, what prompted you to go, "You know what? Hey, I think I can have the solution for this or I can have the answer to this." [00:04:38] Dr. Shalabh Gupta: The first question that you ask, understanding the unmet need in medicine, there are a lot of problems that you can address. So, to give you a framework, if I am thinking about a problem, I want to understand if a couple of things, and in order of priorities, these are: can I find a solution that with my resources-- resources is time, energy, and money-- can I create a product that will truly make it to the market? Number two is that I also feel that one can get very blindsided that "I have a solution," but not understand what other solutions exist in the market. So understanding the competitive landscape. If I create this drug, this device, this product, and it is going to take three to four years in the market to come to the market-- which, by the way, in medical word is a still very fast track because it takes much longer-- what will the competitive landscape look like for 5 years down the road? So that's the second part. And third is that what is the solution that I'm developing? Is it unique in terms of having a novel, either as a drug device or drug device combination, or as a patented drug, patented device, because in our industry, it's not really possible to scale up something until unless you have an IP or intellectual property protection. And then from there onward, the last thing is also, who's going to fund me, how I think about funding, not for next six months a year, but also a continuum of the product development. If I think about all these 4-5 problems, then you start to narrow it down. There are some problems that are very much worthy of exploration. For example, treatment of Alzheimer's, we all know it's a big unmet need, we all know there's a big market opportunity. But I realized that was something we couldn't do it with the products or the development candidates that I had seen. So, being able to define where is the end point and goal. Being able to understand, can I make an impact? And when I say I, I speak for myself, but each one of us, I always remind entrepreneurs, we each one of us have our own deck of cards. We have to play with our cards, we can't compare ourselves with somebody else, or we can compare some other cases study. So understanding more about what is so unique that I can bring to table that can I make a difference and then making a business around this where the thesis lies. Once you identify that, then there's a question about continuing to execute and keep changing your plan as you go along. [00:07:11] Lindsey Dinneen: Yeah, absolutely. Well, I love your framework for thinking through all of those things. And so of course you use that when you thought, "Hey, here's this issue. I could potentially have a solution," and you went through this process. And then can you tell us about your innovation now and how that is helping and how you expect it to help change all these wonderful lives? [00:07:33] Dr. Shalabh Gupta: So, so for treatment of kidney diseases, first of all, it has been one area of development that has not had that much of innovation. And, and I think that is where the initial part of the thesis was that focusing on nephrology of kidney diseases is not same as developing a drug for cancer treatment. Cancer treatment changes every six months a year. The standard of care continues to evolve. Is there an unmet need in cancer treatment? A hundred percent, but the part is that the pace of innovation is very rapid. Is it same in nephrology? It's getting there, but it's still the development of a new products in nephrology still is not at the same pace. So I thought there was something we could make a difference by a small company. The drug that I acquired from another company was a drug that had finished a clinical trial. So it had shown that the drug is safe. It had also shown some signal of it working in healthy volunteers. That's a phase one trial. And the innovation came from a car battery company that had figured out how to make a big, large size pill to make it smaller. And sometimes greatest innovation, greatest insight come from the fact that when I talk to the kidney doctors, the physicians who take care of these patients there with the treatment of kidney diseases, they said the problem for these patients are the patients have to take 12 to 15 pills per day. And this innovation allowed us to be able to make that number of pills go down from 13 to 12 or 15 to three pills per day, one pill with each meal. And then the regulatory pathway became a bit more clear that if I can show that our drug is similar to the drug that was in the market, maybe there was an opportunity to go through expedited pathway, which is what we did. And I acquired the drug in 2018, went to FDA right after acquiring the drug to expedite the pathway again, thinking about de risking the development pathway. And as I mentioned in 2025, we are expecting the approval. So that is the process about it. And that's the story behind the lead drug. [00:09:51] Lindsey Dinneen: Great. Excellent. So that is really exciting. And as you continue to go forward with this company and the innovations that you're creating, what is your ultimate goal or dream that you're really striving for? [00:10:06] Dr. Shalabh Gupta: So, the focus for Unicycive is building new novel treatment for kidney diseases. Our lead drug is expecting approval in June 2025. But we have a second drug in development, and we continue to think about what will be something that we as a small company can bring to market. There are other areas of unmet need in kidney treatment. But instead of doing too many things at the same time, we continue to think, "How do we grow our company? What will be the vision for the company three years down the road, five years down the road?" And what we want to continue doing is to develop the drug candidates, advance them. Right now, after the first drug we get through approval, it will be the second drug. There is a thought process behind it. One of the biggest challenges that I've seen for smaller companies and startups is that they end up in doing too many things at the same time, which is difficult to do, even for big companies. You know, big companies, they have a one product that is a marquee product, they launch that and then they develop other things. So, being able to stay focused is also key because you can have a lot of energy, you can have a lot of ideas, but you have to focus on which one you can do first. [00:11:22] Lindsey Dinneen: Yeah, that is so true. It's such great advice, a good reminder. Yes, focus is so important. You know, honestly, that's probably one of the tricky things that startups in this particular field might struggle with is that focus. So I'm wondering what kind of advice do you have for say a brand new entrepreneur in the industry who has these great ideas, but you know, maybe has so many that they're a little too scattered. [00:11:52] Dr. Shalabh Gupta: Right. So, I think you may start with 10 ideas but the framework I gave you that: can this idea in this given timeframe with my resources and the funds that I can raise, can it make a difference? So you start to narrow it down. You start with a big funnel, narrow it down. And then maybe you have two or three ideas. Instead of thinking to yourself that "No, I'm not going to tell my idea to anyone because somebody else can take it away," find people who will be willing to pressure test those ideas. Then you will have identified something, maybe one Idea that is worth the pursuit. So then you focus on that. So that's one part of how to triage it because we all have ideas, but those ideas may not be worth developing once you go and talk to the marketplace. And marketplace is your investors, the physicians, and the patients. I keep saying about these three stakeholders, because if physicians cannot prescribe what you are developing, then it's of no use. If patients don't necessarily benefit, then it's of no use. And if you cannot get insurance companies a reimbursement for that means the product will never get here. So it's a process, but nobody can come up with an idea. And there is no great idea. There are ideas that you have to, and then once you find that one idea that resonates with all the stakeholders, physicians are excited about it. If you talk to patients, and you want to do that early on, you don't want to develop an idea and then go, you know, that is the greatest idea but nobody really perceives it that way that except you and a couple of your friends and people who work with you. I don't mean in a bad way. I mean, that you want to be able to test this idea very quickly. So once you get that idea, once you identify what is that the company should be focused on, then the question about is actually building an execution plan. And the only advice I can give is that at any given day for a company, startup, especially whether you're a founder or you're a founding team member, the list of priorities is 50, 5, 0, or maybe 100. It takes time to figure out of those 50, which are the top three that are most important and then being able to focus on those three. You know, the reason I say that no one can work on 50 priorities at the same time. But we all can take two or three priorities and say, "These are the three things that I'm going to work on today. That is this week. Those are the things I'm going to do this month." And therefore you start to develop identifying priorities. The right ones takes time. Sometimes it is a fundraising. Sometimes it's a building a team. Sometimes it's a product development. Sometimes it's all three of them, but being able to allocate your time and energy and focus is a key. People say it's the question of money. I don't think it's a question of money. Money is one of the resources, but the biggest resource we all have is a time and energy and focus. In a company of our size, we are a publicly listed company, and we now have grown from where we used to be, and it's still small. Even today, there are a lot of things we choose not to do. We choose not to go to conferences. We choose not to publish papers. If something is a priority to us, we say, "This is the only thing we're going to focus on. This is the next three months, this is our main goal." And every team meeting I have, I always remind people, three priorities. More than three, way too many. One may not be enough. But because if you can't remind people, what is the priority for the company, then you will not succeed. It is a very challenging environment to think about a startup company or companies in general. And when you have too many priorities, you tend to lose focus on. By building priorities, having priorities, executing them. You create momentum, you create confidence. They create success and you keep climbing the ladder. But truly the biggest challenge for us in the beginning of the career is that identifying which are those three priorities that matter. And once you have had some experience, then the challenge is to keep those priorities and change them as you go along, right? As you go along, you have to continue to grow. For example, in the beginning, it may be the five people you have and that may be enough. But as where we are in the company, it's a question about growth of the organization, right size, not too many people, not too little, hiring enough people so we can continue to execute on our vision and the promises that we made to ourself and to our investors. [00:16:27] Lindsey Dinneen: Thank you for that advice. That was fantastic. And such a great way to narrow it down and help people understand how to narrow down so that they can actually focus and succeed before moving on. I love that. Thank you. So, you know, looking back over your life, and of course, you've had such an incredible career that has really taken you in a lot of different directions. Could 10 year old you have ever anticipated where you'd be today? [00:16:54] Dr. Shalabh Gupta: I don't think so. I think I think we all have a what I call a true north compass. What I did think at the 10 years of age, if I can go back, maybe 10 is too early but maybe 15 or 16 or 17, that hasn't changed. Let me tell you 2 things that I always felt most inspired and excited about. Number one was that I wanted to be in healthcare because, intellectually, I like biological sciences. I felt, "My gosh, what could I do with that if I could make a difference?" And number two was that I, from very early on, I wanted to be something which could help people directly. As you know, there are many ways you can help people, but being in medicine or healthcare, I felt there was a direct impact. Now, looking back after several decades, I feel that part of the influence was my dad. My dad is a physician, continues to see patients and do pro bono work. So that had a very lasting influence on me. That helped me to think about, okay, this is what I want to do. Then being trained as a physician, then going to work on Wall Street, then there was a question about understanding how the impact can be broadened, if you will. The way to think about what I do today versus what I did, say, as a physician, physicians see, say, 10 patients, maybe 12 patients if you're seeing an outpatient basis per day. And if you're in an ICU or ICU doctor, an ER doctor, you could see more number of patients, but then smaller time. And you multiply that impact that many patients, let's just say 10 patients per day, and you work at 300, 350 days, 360 days, 365 days, don't take any break, but that is that many patients a year. What we do today has a potential to impact hundreds and thousands and millions of patients and not just in the U S, globally. So from one vantage point is just magnifying the impact. And the other vantage point is doing what I would have done before. I still love sciences every day. My job is to not just talk about business, but also think about, "How do we fundamentally solve the problem?" And having had those experiences you know, it helps you to keep yourself grounded. One part, I know this wasn't your question, but one advice I can give people who are thinking about developing their careers as an entrepreneur, if you are a founder and CEO, especially think about your career or skill set as I spoke, a wheel, a circle. Every skill that you have, some of us start with more technical background, like me and MD. Then you have to develop their finance and business skills and the business development skills. So sometimes people say, "Well, you know, ABC went to grad school and they dropped out of grad school and they started a company." That's wonderful, but think about much longer beyond a two-year, three-year, five-year time horizon. And that's what helped me to think about my career. So I worked on the Wall Street, but that gave me a finance and understanding about how public companies are valued, not just by the company, but how stock analysts value the company, how investors value the company, what moves the stock, what did Genentech to understood. That gave me the chance to understand how a big biopharma company thinks about their product development. And at Genentech, in some interactions we have had, we were looking at the products from other smaller companies, either to collaborate with them or to acquire those products. So that's a different skill set. I went very early on, as I said, in my career, I went to FDA. So even though I'm not regulatory expert, but I understand how agencies think about the product approval so that helps you to make a more of a holistic viewpoint because the business has become more complex, and you cannot just have a only business degree and you say, "Well, I'm going to succeed." Some people have rounded that up by years and years of experiences. And then there is also innate desire to learn. I learned from not just doing the work I do every day, but my, my, you know, talked a lot about it. I read anytime I get I read books that are not related to medicine, that are not necessarily related to health care, because you have to understand how to grow a revolution. You have to understand leadership skills that are not necessarily taught in schools. So, you have to find a way to continue to refine yourself, because the only way you can create a great company is to become a better version of yourself. [00:21:31] Lindsey Dinneen: Thank you so much for talking about that and for sharing your advice. And I love that image of the wheel. It's a good reminder that sometimes life takes you on very interesting tangents, but sometimes they all do merge at some point. You've got this little sliver of this knowledge that you're working on, and then this experience, and then they start building and I really love that, that, that way of thinking about it and also remembering that It's very useful. So, so like even earlier, I was struck, you talked about how there was inspiration from car batteries, right? And so how interesting is that to go from, what you might expect within your industry, here's how to solve a problem. But then you guys went outside and said, how do other people solve problems? Like maybe we can borrow from that. And I think that's really cool. [00:22:21] Dr. Shalabh Gupta: And I also think that if you stop focusing on only in your industry, learn from anywhere. Some of the best learnings that I have personally, that felt inspirational to me, did not come from biotech companies. They come from tech companies, truly. When you think about the worst, most successful tech companies like Amazon, Apple. I can go on and on, but there are things that you can learn from them. There are things you can learn from the founder of Amazon, Jeff Bezos. He talks about building Amazon and he talks about doing many experiments at a smaller scale that fail at Amazon in order for them to succeed at a few that really work. And this is where I was saying that culling the ideas, you may start with 10 ideas, but no one can develop 10 ideas, no one. And it's not because of money. People say, "Well, that if I had money." There have been numerous examples where companies have been funded with lots of money and the companies fail. Part of the problem is that when you get too much money, I think you may not realize that you still have to deliver. Because focus and execution takes really knowing what the target is, and then hitting the target and not one time and time again. Targets may change, but the companies cannot focus in 20 different things. In the beginning, you have to start with a very key thesis. [00:23:39] Lindsey Dinneen: Yeah. Absolutely. Absolutely. And yeah, so learning from other industries, and that actually kind of also brings up a thought. So as you've gone along in your career and you've had many different iterations of who you are and what you bring to the world, now, are there any moments that really stand out to you as affirming, "Yes, I am in the right place at the right time?" [00:24:04] Dr. Shalabh Gupta: Yeah, that's a very good question. And I have had a chance to think about it every now and then. So there are there, there are certain observations I'll make. You know, people always say, " What will be your dream job?" And I think the dream job for someone is the job that which you will do any given day, and you will feel a joy that you're doing it and you're not doing for remuneration. You're not doing because you're going to get paid. And we all have those different moments in time. People talk about "flow" where the time stops because you're doing something so deeply engaging that you lost track of time. You forgot where you are. You're not feeling tired. For me building of this company and the team that we have assembled at Unicycive is that flow. Any day that I'm not traveling, I am in my office. I don't work from home. I am every single day in my office. And sure we have a small team, but when we work with the team, these are motivated, driven people with decades of experiences. We feel that we are in a common mission, like we are solving the world's greatest problem. And I know that may be exaggeration, but that's how it feels. And being with them in a room and thinking about a complex problem-- and not just thinking of a problem like how big companies think about it-- but thinking of the problem in a scientific way, but delivering it a solution that only a small company can do that to me is a joy. Number two part is that as I've gone further on my career, I, I am a mentor to a number of startups from Stanford and UCSF, and many Stanford companies, many of them come with a very different problem than purely a biotech company. Since the pro bono work, I do this because I find by telling other people from their problem, I get to reflect on my own problem, and I do that on every quarter. There's one or two companies and I've been really privileged. I feel one of the greatest joys to meet with these great CEOs and Stanford has been a great collaborator. They have a program called Start X in which they have these companies that are participating in a accelerator program. And Stanford's accelerator is different and unique that they don't take any equity. They provide you the opportunity for mentorship. I was part of that program many years ago. So I meet with the CEOs and many of these CEOs will come very different problem. As an example, there is a company that's focused on artificial intelligence using interaction between a physician or healthcare provider and patient, and being able to use AI to streamline that interaction. That is a point that I saw of 10 years of clinical practice, how that communication is broken, literally is broken. Patients go to doctors, not because doctors are the world's greatest knowledge source, but patients at the end of day, they need someone to help them feel better, help them understand the problem that the physician can solve it. What ended up in being in today's healthcare system in the U. S. is that doctors have become mechanical and not because doctors are bad, because we are given these many things to document these many things to chart. If you talk to a physician, a primary care physician, many times the physician is sitting behind the computer screen. Those bedside manners are gone, like literally they are not there until you go into concierge medicine because the physician has to fill up this chart. I practice medicine. So understanding how this company and this CEO, this entrepreneur is trying to solve that problem, I lean back to the years of clinical practice. Then I lean back to the building the company. They're prioritizing it, having three priorities, having five priorities, and then being able to understand. And every company has some things which are similar, growth of your product development, continuing to advance the company, continuing to tell the story, attracting the right team members. It just gets magnified at a broader level. But the problems start similar, very similar. You know, think about when we talk about tech companies, Apple, the first thing they had to do, develop a product, then build a team, then sell the product, tell the, sell the vision, you know, and then continue to raise money. And that part is seems sometime very lonely. It also seems that I am uniquely burdened with these problems. And I always remind people, "You know, as much as you would like to think that you are unique. I assure you, it is not a problem that we are gifted with. We all have to face the same set of problems, sometimes more, sometimes less." So then you start to take them less personally. You start to say, "Okay, I'm not the first one to face this problem. These problems have happened to people like me before and they will overcome. How can I do it?" Then you'd become safe, a solution based thinking versus a place where you get overwhelmed with the problem because problems exist. And if anyone is listening to this podcast and if they've developed a started a company, I can assure you the problems come with a flood. They are not going to end ever. So it is disappointing. Sometime it feels that, "Oh my gosh, it is me versus the world," but it is not so. If you have good set of mentors, people who are not directly involved in day to day in your business, there are people who can help you think through it. And that is something that I find a great joy in talking to these CEOs, being able to help them understand the problem. And I say, you know, a couple of hours a month, but then when I go back to my own work, one that I realized this was the same problem I faced a few years ago. Two, it's a similar version of the problem I face at a slightly larger scale today. And three, being able to step out of from your own narrow zone, it gives you perspective. Then what I said to you about that problems are not, these are not personal problems. These are the problems we all face developing a product. It doesn't matter whether you healthcare. People tell me health care or product development is really hard. You talk to my colleagues, our CEOs who are running tech companies. Products in development and tech companies may seem easier, but to create a great product that truly solves customers problem, it's not easy. [00:30:30] Lindsey Dinneen: Yeah, and well, I love that mentorship and sort of teaching and guiding, giving advice to the next generation is something is of a core value of yours and something you really care about. And it actually is a great segue into my next question, which is just pivoting the conversation for fun, imagine that you were to be offered a million dollars to teach a masterclass on anything you want. It can be within your industry, what you're doing right now, but it doesn't have to be. What would you choose to teach? [00:31:02] Dr. Shalabh Gupta: I think as much as we all feel that entrepreneurship is an external game, I think it's a lot of internal mindset, being able to understand yourself better. Being able to understand who you are, what are your true core values, what really drives you. It takes time and it requires a continuous interrogation, asking yourself, "Is this really what I enjoy?" Some of us feel it's a glamour that we feel like we want to be CEO. Some of us would be better off as a CTO, Chief Technology Officer. Some of us would not want to do startups. It's not for everybody. And it's okay because you can work in a bigger company and can be, you know, people talk about entrepreneurial pursued within a large organization. Maybe that's what for you. But being able to understand yourself, it's a very important part. And I think unfortunately, formal education does not help us no matter what degrees and which schools. And it really doesn't matter whether you a science degree, MD, PhD, or your business school degree like MBA, we're all very uniquely different, and we have different values. What one person sees inspired by, for somebody else, it may be a nightmare, you know. It's a thing that people think that startups are so much fun. I read a joke. It says, "People leave 9 to 5 job to work from 5 to 9, which is 5 a. m. to 9 p. m." So I think that's because this is some truth to it. And I've said to people again and again that if making money is your objective, please don't go as to run a startup. It is probably the worst way to think about pursuing the financial part. You do something because you have a faith and belief in something. And it doesn't have to be the faith about changing humanity. It's about something that you have a unique skill set or unique product idea that you believe you can bring to the marketplace. The biggest focus we all can have is making an impact. If I can serve a large number of patients, I can serve a large physician, I will have a product that will make money, therefore, that will make money for enterprise that will make money for investors. And therefore, as a company, we will make money. It's a very simple truth, but we like to make it complicated. I really mean it. The more I got to understand this part of the process better, which goes back to the basic thing that I said to you, if you said that you have a master class, the one thing I will say to you, it's spend time to understand yourself. And it's okay to realize that what I thought I like, I don't like it. The part that I talked to you about flow, it takes efforts. I've had many careers, but when I work in my company, the time can stop for four or five hours, literally we can be working on something. And I have a team and it's not just me alone. I have a team that when we think about a problem, these are people who have spent three decades in working in different companies, large, small, many size companies, we could work cohesively, collectively, think about a problem. And that to me, it's a joy. For me, that is a creation, right? You know, we're thinking about the problem, which may be a design of a clinical trial, because we have to think we have to use brains. And I always say, "God gave us a gift, which is a neuron. So use it, let's use them." And challenge yourself, right? And the challenge in a good way, not be a condescending ending jerk and say "No, how could you do it?" I try to say to people, "Look, I understand this is how it is done, but I want to do two things. Number one, please believe me that we can do better, faster, cheaper. And number two, I promise you that whatever I'm telling you, I'm not going to tell you and walk out of the conference room. I will work hand to hand." We call it a hand to hand combat is essentially that I'm not just telling you I'm going to work with you. I want to find the solution, but we can't do that thing that are you used to. Every trial, people tell me it's going to take 18 months, 12 months, it's going to cost as much. We shrink that thing timeline cost by not 10, 20%. We talking 50%. And these are people have done this before. So, so I need the courage to be honest and say, "No, we can't do it. We have to do it faster, better, cheaper, but how?" And then asking them. So, I say, "It's okay that we walk away and we don't have a clue. It's okay. Today's Thursday. Let's come back. Take three days to think about it." But the reason is that because when you ask yourself from a place that I can't do it, the mind is start to find solution versus when you say, no, I can't do it. Because in that case, it's a subconscious mind that keeps on giving you 15 reasons why you can't do it. People talk about growth mindset. I've always said to people, "We may not be able to do this thing today, but the understanding that with a little bit of help, a little bit of patience, a little bit of it, making ourself better, we can become that company, we can become that organization." And that really requires challenging ourself. And that's where I went back to. I want to go back to this question you asked earlier. People talk a lot about entrepreneurship as if it is some very specific skill set. I think because if you know yourself, you know what is your true zone is, then you want to surround yourself places that you are either not good at, or you don't enjoy doing it, right? In the beginning, it is just you and a vast amount of problems to face. Then you start to build your team. Then you start to see yourself, "You know, maybe Bob can do this work. I really, I'm not that good at it. I don't like doing it." Then you start to rely and surround yourself with not same skill set, but the people who are complementary skill set. And that's how you build a team. That's the foundation of team. Then you build trust and you say to Bob, "Whatever you do, it's not your fault. I'm here to protect you." You don't point fingers at each other. We always remind the example of Navy SEAL. You know, I've never worked in the US Army. I was not an Army veteran, but the ethos that Navy SEAL uses where the team wins, I always tell people we are a winning team. We are not looking for MVPs, you know, because the teams win. Teams create products, teams create value. Individual glories is not useful and this is something you have to keep reminding us that we keep drilling it down and say " No, it's not Bob. It's not John. It's not James. It's us. It's as a team." Again, as you grow through the company stages, your skill set has to continue to evolve and people always say, "Well, how do you lead a team?" The first thing that I always said, "Every single person in my team, you are a leader. Why? You wake up in the morning, brush your teeth. You're leading yourself." Really! Like, what do you do with your day? If you happen to be a parent or partner, a spouse or somebody, you have people you influence around yourself, right? So instead of worrying about, "Oh, you know, I want to lead a company." First, you have to lead yourself and you have to lead with courage. It's starting a company, building a company, right? Yeah. No matter what the media tells you, it is hard. It's hard to develop a product. It's hard because the challenges are not one or two. There are many. Being able to drill down, saying "These are the three things I'll focus on. These are the only things that matter." And then if something new comes up, you have to face that challenge and put the third in your list. It comes in a different page. You know, I use this basic exercise. I have a notebook, a physical notebook and not electronic one, and a piece of paper. What are the top three priorities? And then the other part is that I've asked people to do this exercise when startup companies, CEOs come and tell me all their problems, all the things they want to do. I said, "Humor me if you will. This is the end of the year. And let's say today is we are in 2025. What would you like to tell yourself a year from now? If everything happened the best you could imagine, how many customers, how many products, what will be the stage of product, who would have funded you? Who are the people behind you?" And I asked him to write in a whiteboard. And I say, imagine, no, this is the five thing. If they write 25 things, I say, "No, this is down to five things. What are those five things you would like?" And again, everything has just gone and you can't believe you're sitting there. What will it take? Is it this? And then you start to have a goalpost, right? It's a target. Then you work backward. [00:39:37] Lindsey Dinneen: Yeah. Yeah. Well, that's great. That is such great advice. So thank you, first of all, for sharing, but I think in general, your masterclass would be so much-- you'd have to have a full day or more. That's great though. I love that. How would you wish to be remembered after you leave this world? [00:39:57] Dr. Shalabh Gupta: That's a very good question. That's one that I ask myself every day. The most important thing for me is to be who I am to make a difference for people who are around me. For me, my family is very important. I have kids and I always think about it. What will my children remember? Then it comes down to people who work with me. We want to give an experience to people. I've had people who have worked for I keep saying it two or three decades. My true wish is that I always say for whatever time they work at Unicycive, I want them to be remembering this is the best time they work for a company and that is the best hope we can do it. Because as a entrepreneur, if I can make our company the best experience, best environment, then that creates the best products. And a company like us, we realize that we are going to face challenges and it's not a question of this, the question is how many challenges. The question is not going to be, "Will the challenge defeat us?" The question is, "How do we overcome the challenges?" So it's about growth mindset, having a very distinct, clear vision and empowering people. And last thing is that what we do in healthcare affects millions of people people. Our drug is not going to be just in the U. S. We have partnerships outside U. S. We think about patients in China, South Korea, Southeast Asia. We are talking to companies in Europe. It's an opportunity to make a difference globally. And that is what keeps us going. That's what, you know, when that's when I talk with flow, that is what makes you want to work, whether it's a weekend or whether it's a late evening. And I think that is something which we all need to do to find something that is meaningful. And meaning means different things to different people in different phases of life. So it doesn't have to be, you know, I tell even my own team member, " Unicycive does not have to be the purpose of your life, but let me help you to manifest your best version so you can work well, because you are working here, you are spending your time, might as well make it meaningful for you and for the company." So finding that balance is key and it's a constant challenge. I never take anything for granted. It's a constant to my own team members. How can we make it better? You know, people always say the company grows and we started with the company. We went to IPO with one person. That was just me as an employee, which is not a common thing. I frankly don't know any other company that I've ever seen that went to a straight IPO with one employee. But that wasn't about me. It was about building the company, building the team. Today, we have 25 or so more, but it's still a small team. And people always ask me, "How do we go from 25 to 50 and it still remain the same." I said "Exactly how we became 5 to 10 to 15, 15 to 20." Because if you keep the culture same, focus same, and you remind people that it's not about who we are individually, but it's what we could be collectively. And you have it going and you know, something you're passionate about, you will give all that you got and then some more or else there is not worth fighting for because life is hard and building a product developing a technology or running a company is hard. So, either you are a full believer or else you can't do it. I mean, if you can do it, it's going to be miserable on both front. You want to do a good job and you will find it very difficult. So. [00:43:24] Lindsey Dinneen: Yeah. Indeed. Yeah. Excellent. Well, and then final question. What is one thing that makes you smile every time you see or think about it? [00:43:36] Dr. Shalabh Gupta: I think when you look back on the challenges that you once thought were unsurmountable, and then you say to yourself, "Huh, that was just a curve in the road, not a roadblock." Then you start to smile because of not because how smart you are, but how much together a team can accomplish. And you start to find, if you're working in a company setting, you start to feel that people start to feel empowered. My team says that you did it. I said, "No, we did it. I just showed you a judicious path, but you did it. I didn't do it. All I said to you is to change your framework." Because it's a framework. It's a mindset. And I keep saying about mindset because if you come with the idea that " No, I only, I need this much money, this much time, these many resources," you'll find you the subconscious mind keeps on validating those challenges. But if you say, "No, people like us have done it before I can do it, we can do it." And give them the time and space and say, "Look, you don't have to have an answer right now, but please go back and just think about it." Then they come back with the answer and they themselves surprised. But it truly requires a authenticity, a vulnerability, and being absolutely willing to fall on your face and get up and just fight again. And that's part people don't realize. People think about that every company is a smooth road up, but the companies go through the cycle. It's not when you're going up, it's what happens when you fall down. Can you pick yourself up? And it's not just with your team, but with your investors too. You know, we thought that we're going to file an NDA in 2020. You know, 2024, we had planned for everything and the whole thing was there, but we ended up in having to run an additional trial and then you have to communicate with integrity through transparency. This is what happened. This is what is there, but we can accomplish that. So then that all of all that helps you to look back a smile, laugh and say, "Okay, I accomplished that. We can do the next one." And that keeps the growth happening. And at the end of the day, we are not happy because we accomplished small things by doing small effort. Most of us as human beings want to be challenged in the right way and we feel joy in doing hard things that take a lot of efforts and once seemed just impossible to do it. And the question is, can you do it with your entire team, not just personally? And that's what inspires people. We want to be that company that people want to work for not because they need a job, not because we can take care of their 401k. I mean, those are a wonderful thing and I'm blessed that we can do all of that, because once upon a time, we didn't have any of that. So I don't take it for granted, it is something. But the fact is that what was the mission hasn't changed ever. And you know, that that is something which is worth pursuing it. And I think if people start to see that they can accomplish that, these challenges are not personal, that they are bound to come. And then they have a support group, you know, we all need somebody other than ourselves and people whom we are surrounded with somebody to hold our hand and say no, you fell down, but it's okay. You can get up. I think it's that support system, right? The more you can have it, the more different types of people you can relate to and call them friends, mentors, that helps. And I have tons and tons of them because my gosh, I mean, there are days seems like, how would I ever get out of this? As much as you may think that I have all the source of inspiration, but then if somebody else holds your hand, they say, no, you can do it. That is what gets you going to the next step. [00:47:25] Lindsey Dinneen: Absolutely. Well, goodness, this has been an amazing conversation, just packed full of incredible, helpful advice, and just very practical down to earth sharing. So thank you so much for your time today. I really appreciate everything you're doing to, to make an impact. So thanks again for your time. [00:47:44] Dr. Shalabh Gupta: Thank you very much. Thank you for hosting me and thank you for your time and interest. Really appreciate it. [00:47:49] Lindsey Dinneen: Of course. We are so honored to be making a donation on your behalf today to Feeding America, which works to end hunger in the United States by partnering with food banks, food pantries, and local food programs to bring food to people facing hunger. And also they advocate for policies that create long term solutions to hunger. So thank you so much for choosing that charity to support, and we just wish you the most continued success as you work to change lives for a better world. And thank you also to our listeners for tuning in. And if you're feeling as inspired as I am right now, I'd love it if you'd share this episode with a colleague or two, and we will catch you next time. [00:48:31] Ben Trombold: The Leading Difference is brought to you by Velentium. Velentium is a full-service CDMO with 100% in-house capability to design, develop, and manufacture medical devices from class two wearables to class three active implantable medical devices. Velentium specializes in active implantables, leads, programmers, and accessories across a wide range of indications, such as neuromodulation, deep brain stimulation, cardiac management, and diabetes management. Velentium's core competencies include electrical, firmware, and mechanical design, mobile apps, embedded cybersecurity, human factors and usability, automated test systems, systems engineering, and contract manufacturing. Velentium works with clients worldwide, from startups seeking funding to established Fortune 100 companies. Visit velentium.com to explore your next step in medical device development.

The name of the biopharma game this season is vaccines—and RFK Jr. wasted no time returning from Memorial Day Weekend before making news on this front, removing the COVID-19 vaccine from the list of recommended immunizations for healthy kids and pregnant women on Tuesday. This follows a rash of recent moves, including a new risk-based strategy for the approval of new COVID vaccines focused on adults over 65 and high-risk individuals six months to 64 years of age and a request that Moderna and partners Pfizer and BioNTech update the myocarditis risk on their vaccines' labels.This increased vaccine scrutiny by the FDA and Department of Health and Human Services is having a significant impact on biopharma companies, several of whom have received stop-work orders on next-gen COVID vaccines. Meanwhile, Moderna last week pulled the biological license application for its combination COVID-19/flu vaccine, anticipating a request for additional data on flu shot efficacy from the FDA, as mRNA technology continues to be scrutinized after playing the hero during the pandemic. Also last week, the White House released its Make America Healthy Again (MAHA) report, which took aim at vaccines, along with pharma lobbying and GLP-1s.Also on the policy front, a California judge issued an order Thursday that indefinitely stops HHS' goal of reducing its divisions from 28 to 15 and firing upwards of 10,000 employees, among other reorganization and mass layoff plans. And speaking of government plays that could receive judicial pushback, we received a couple of new updates on the Most Favored Nation (MFN) front: first, President Donald Trump appointed his CMS chief Mehmet Oz as the leader of drug pricing negotiations, calling him “one tough hombre,” and second, HHS provided new guidance for streamlining the process for states to import drugs from Canada.In the obesity realm, Eli Lilly is calling out the Centers for Medicare and Medicaid Services. In an open letter last week, Lilly voiced its displeasure with the agency for a final ruling that left its Zepbound and Novo Nordisk's Wegovy out of Medicare Advantage and Part D coverage in 2026.And in the R&D realm, we returned from the long weekend to sad news from Rocket Pharmaceuticals, as the company reported that its pivotal Danon disease trial is on hold after the death of a young patient. The death—extremely sad on a human level—is also a setback for the gene therapy space, which had been buoyed earlier this month by the success of a personalized CRISPR treatment received by baby KJ.Finally, BioSpace looks ahead to ASCO#25 where Dan Samorodnitsky will be on the ground in Chicago.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über Nvidias neuen KI-Billigchip, Hoffen auf das Pharma-Revival und was diese Woche sonst noch wichtig wird. Außerdem geht es um VanEck Uranium and Nuclear Technologies ETF (WKN: A3D47K), Uranium Energy, Oklo, Nuscale, Health Care Select Sector SPDR (WKN: A14QB2), CVS Health, United Health Group, Eli Lilly, Cigna, Danaher, Thermo Fisher Scientific sowie Gilead, Sandoz, J&J, Roche, Sanofi, VanEck Quantum Computing ETF (WKN: A418QM) Google, IBM, Microsoft, Sony, Boeing, Honeywell, IonQ, Rigetti und D-Wave. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Jim and Jeff discuss this healthcare stock. Become a CNBC Investing Club member to go behind the scenes with Jim Cramer and Jeff Marks as they talk candidly about the market's biggest headlines. Signup here: cnbc.com/morningtake CNBC Investing Club Disclaimer

Ireland has become a major base for US pharma companies, including Pfizer, Eli Lilly and Johnson & Johnson. That's bolstered the economies of individual towns and played a role in the country's massive budget surplus. Now, US President Donald Trump's tariff threats are bringing a dose of uncertainty. The FT's Ireland correspondent Jude Webber traveled to the town where the world's supply of Botox is produced to see what impact potential pharmaceutical tariffs might have on the country. Clips from WKYC, The Journal, Bloomberg- - - - - - - - - - - - - - - - - - - - - - - - - - For further reading:Trump tariffs bring furrowed brows to Ireland's Botox townTrump's tariffs threaten Ireland's pharma fortuneIreland's luxury problem: what to do with its €8.6bn surplus- - - - - - - - - - - - - - - - - - - - - - - - - - Follow Jude Webber on X (@jude_webber), or on Bluesky (@judewebber.bsky.social). Michela Tindera is on X (@mtindera07) and Bluesky (@mtindera.ft.com), or follow her on LinkedIn for updates about the show and more. Read a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.

Listen as Gaining Health host, Karli Burridge, reflects on the OMA Annual Conference with Sam and Joe!Petition to keep Zepbound on formulary:  https://www.change.org/p/stop-cvs-caremark-s-zepbound-ban-restore-coverage-of-the-superior-obesity-medicationSandra Christensen is board-certified as a family nurse practitioner and holds the Certificate of Advanced Education in Obesity Medicine from the Obesity Medicine Association. She is the founder and Chief Clinical Officer of Integrative Medical Weight Management in Seattle, Washington, and has specialized in obesity management since 2005. She is a Master Fellow of the Obesity Medicine Association and a Fellow of the American Association of Nurse Practitioners. She serves on the Board of Trustees for the Obesity Medicine Association and is the President of the Washington Obesity Society.  She authored the book, “A Clinician's Guide to Discussing Obesity with Patients” published by Springer, and was named the 2022 Obesity Medicine Association Clinician of the Year.The Washington Obesity SocietyIntegrative Medical Weight Managementhttps://www.linkedin.com/in/sandra-christensen/Joseph Zucchi (pronounced Zoo-key) is a board-certified Physician Assistant and Personal Trainer who serves as the Clinical Supervisor of Transition Medical Weight Loss in Salem, New Hampshire. With over a decade of experience in obesity medicine, Joe leads a multidisciplinary team dedicated to helping patients achieve sustainable weight loss and improved health. He has worked with over 2,000 patients to collectively lose more than 40,000 pounds. Joe integrates fitness, nutrition, and medical interventions to provide comprehensive, patient-centered care.  His work has been recognized through multiple accolades, including leading Transition Medical Weight Loss to win awards for best weight loss center in NH. He has written articles and has shared his expertise on obesity care and weight-loss treatments in outlets like the Wall Street Journal, MedPage Today, Healthline, and Doximity. Joe also is a speaker for Eli Lilly and educates other providers about Zepbound and obesity medicine. https://www.linkedin.com/in/josephzucchi/https://x.com/JPZfitnesshttps://transitionsalem.com/Support the showThe Gaining Health Podcast will release a new episode monthly, every second or third Wednesday of the month. Episodes including interviews with obesity experts as well as scientific updates and new guidelines for the management of obesity.If you're a clinician or organization looking to start or optimize an obesity management program, and you want additional support and resources, check out the Gaining Health website! We offer a Roadmap to starting an obesity program or practice, pre-recorded Master Classes, digital resources including patient education materials and office forms, and much more! Check out our resources on our Gaining Health Shop! If you are loving this podcast, please consider supporting us on Patreon

We all know the big economic stories of the year: the trade war, the tariffs. But there's another — even bigger? — story that hasn't been getting the same attention: the Ozempicification of our diets, our bodies and our economy. On this week's TLDR, we take a look at the transformation underway. Plus, economic indicators are telling one story about a potential recession; the headlines are telling another. Which one is right? And, why does it feel like everyone's drinking less alcohol? This episode was hosted by Devin Friedman, business reporter Sarah Rieger and former hedgefunder Matthew Karasz, with an appearance by Armine Yanizyan, Atkinson Fellow on the Future of Workers. Follow us on other platforms, or subscribe to our weekly newsletter: linkin.bio/tldrThe TLDR Podcast is offered by Wealthsimple Media Inc. and is for informational purposes only. The content in the TLDR Podcast is not investment advice, a recommendation to buy or sell assets or securities, and does not represent the views of Wealthsimple Financial Corp or any of its other subsidiaries or affiliates. Wealthsimple Media Inc. does not endorse any third-party views referenced in this content. More information at wealthsimple.com/tldr.

PRWeek toasted the best international work last week at the PRWeek Global Awards in London. Here's a special behind-the-scenes look at the show with Andy Pharoah, VP of corporate affairs and sustainability at Mars and chair of judges for the awards program. Weber Shandwick was the big winner, taking home six awards from the Jumeirah Carlton Tower, in the heart of Knightsbridge, London.Plus, here's a recap of the biggest marketing and communications news of the week, including Adam Collins stepping down from the top comms job at Molson Coors, major hires at Eli Lilly and Company and Jeep and a tribute to Al Tortorella, a key figure in Tylenol's 1982 crisis response.  Follow us: @PRWeekUSReceive the latest industry news, insights, and special reports. Start Your Free 1-Month Trial Subscription To PRWeek

This featured podcast includes a discussion with 3 experts on managing patients with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC) from a satellite symposium held in conjunction with the 42nd Annual Miami Breast Cancer Conference® in March 2025. In observational studies of treatment patterns in older women with mBC, approximately half of the patients were undertreated, and only half received a CDK4/6 inhibitor (CDK4/6i)-based regimen in the first-line setting. Reasons for undertreatment include concerns about the patient's age, perceived frailty, and underlying health issues. Aging is a heterogeneous process; older patients must receive individualized treatment that is not based solely on their age but on a comprehensive assessment that objectively assesses their overall health and ability to tolerate treatment. This program is designed to help clinicians assess the fitness of older patients with HR+/HER2– mBC, review the efficacy and safety of CDK4/6i in this patient population, and individualize treatment decision-making appropriately. Acknowledgment of Educational Grant Support This activity is supported by an educational grant from Pfizer Inc. Today's faculty are: Hope S. Rugo, MD Director, Women's Cancers Program Division Chief, Breast Medical Oncology Professor, Department of Medical Oncology & Therapeutics Research City of Hope Comprehensive Cancer Center Duarte, CA Professor Emeritus, UCSF Disclosures: Grant/Research Support: Ambrx; AstraZeneca; Daiichi Sankyo, Inc; F. Hoffmann-La Roche AG/Genentech, Inc; Gilead Sciences, Inc; Lilly; Merck & Co., Inc; Novartis Pharmaceuticals Corporation; OBI Pharma; Pfizer; Stemline Therapeutics. Consultant: Napo Therapeutics; Puma Biotechnology; Sanofi. Honoraria: Chugai; Mylan/Viatris. Neil M. Iyengar, MD Associate Attending, Breast Medicine Service Program Lead, MSK Healthy Living Department of Medicine Memorial Sloan Kettering Cancer Center Associate Professor of Medicine Weill Cornell Medical College New York, NY Disclosures: Consultant/Adviser: Arvinas, AstraZeneca, BD Life Sciences, Daiichi Sankyo, Genentech/Roche, Gilead, Menarini-Stemline, Novartis, Pfizer, Puma, Seagen, TerSera Therapeutics. Speaker: Cardinal Health, Curio Sciences, DAVA Oncology, IntrinsiQ Health. Editorial Position: npj Breast Cancer, Oncology®. Equity/Ownership: Complement Theory, Bettering Company. Research Support (to institution): American Cancer Society, Breast Cancer Research Foundation, Conquer Cancer Foundation, Kat's Ribbon of Hope, National Cancer Institute/National Institutes of Health. Contracted Research: Novartis, SynDevRx. Komal Jhaveri, MD, FACP Patricia and James Cayne Chair for Junior Faculty Associate Attending Physician, Breast Medicine Service and Early Drug Development Service Section Head, Endocrine Therapy Research Program Clinical Director, Early Drug Development Service Memorial Sloan Kettering Cancer Center Associate Professor of Clinical Medicine Weill Cornell Medical College New York, NY Disclosures: Consultant/Advisory Board: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jounce Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Menarini Group, Novartis, Olema Oncology, Pfizer Inc, Scorpion Therapeutics, Seagen Inc, Stemline Therapeutics Inc, Sun Pharma Advanced Research Company Ltd, Taiho Oncology Inc. Research Funding: AstraZeneca Pharmaceuticals LP, Debiopharm, Genentech, a member of the Roche Group, Gilead Sciences Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, Scorpion Therapeutics, Zymeworks Inc. The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with ineligible companies. PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process. Off-Label Disclosure and Disclaimer This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

This session explores CMI Media Group's continuous strive for innovation and Eli Lilly's commitment to improving health portrayals in media. Driven by the understanding that onscreen narratives significantly impact real-world health outcomes, this conversation explores Lilly's strategies for addressing the underrepresentation and misrepresentation of chronic conditions in film and television, focusing on actionable solutions for marketers and content creators. Mark Pappas, EVP, innovation at CMI Media Group and Lina Polimeni, chief corporate brand officer at Eli Lilly will share thoughts on the potential of unconventional platforms, like sports, to promote healthier narratives and maintain a human connection in health-related innovation. Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

On this week's Inside Indiana Business with Gerry Dick, we continue our “Business at the Brickyard” series from the newly renovated Indianapolis Motor Speedway Museum. The $60 million overhaul is already drawing crowds and boosting memberships, with new interactive exhibits, STEM learning opportunities and a major spotlight on Roger Penske's legacy. Penske Entertainment's Allison Melangton joins Gerry to discuss how IndyCar is strengthening its connection to fans across Indiana — from porch parties and statewide fan fests to collaborations with the arts community. Also in this episode: Big sales at the State Fairgrounds: Mecum Auctions wraps up nine days of bidding with more than 3,000 collector cars and over $100 million in transactions. Roche ramps up in Indy: The company will invest $550 million in its diagnostics campus and bring hundreds of jobs to the city. Slate Auto chooses Warsaw: The electric vehicle startup is repurposing a former printing facility to build affordable EVs, with production starting in 2026. “100 Days to Indy” returns: The hit docuseries gives viewers a behind-the-scenes look at IndyCar stars and their lives off the track. Sam Schmidt marks 25 years: The racing legend expands his impact through the Driven NeuroRecovery Center in Carmel, offering new hope to people with spinal cord injuries. Higher ed investments: Goshen College opens a $21 million nursing training center, and Eli Lilly teams up with Purdue for a $250 million research collaboration. Trackside eats: Yelp's Brittany Smith shares five fan-favorite restaurants near Indiana racetracks, including stops in Speedway, Kokomo and Hobart. As the Indy 500 approaches, we spotlight the people, companies and communities fueling Indiana's motorsports economy.

In this insightful Market Mondays clip, Rashad Bilal, Ian Dunlap, and Troy Millings break down two of the week's biggest financial headlines that could shake up the markets: President Trump's executive order to lower prescription drug prices and Amazon's strategic acquisition of AMD shares. First, the hosts dive deep into the possible long-term impacts of Trump's new executive order aiming to slash prescription drug costs across the board. They discuss the potential winners—everyday consumers in need of lower medication costs—and the possible losers, notably major pharmaceutical companies that may see profit margins squeezed. The conversation covers how this move could spur much-needed innovation within the healthcare sector, but also draws attention to challenges such as lobbying pressure and lengthy litigation. What does this mean for healthcare stocks like Pfizer, Eli Lilly, Novo Nordisk, Johnson & Johnson, CVS, Amgen, and more? The hosts lay out possible outcomes and the bigger economic picture, including references to Mark Cuban's earlier ideas about drug pricing and fair access.Next up, the crew unpacks the real story behind Amazon's much-discussed “purchase” of $84 million in AMD shares. Is this a direct investment or the result of AMD's acquisition of ZT Group International—where Amazon already had stakes? They clarify the technical details and examine how this plays into Amazon's push for self-reliance in AI infrastructure and chip development, following in the footsteps of giants like Apple making their own chips. The discussion also touches on how this integration of hardware and internal resources could position Amazon for even more dominance in the AI race and tech industry at large.Throughout the clip, Rashad, Ian, and Troy provide honest takes on market strategies, investment insights, and the political chess game playing out in real time. From healthcare innovation to tech self-sufficiency, this conversation is a must-watch for investors, entrepreneurs, and anyone wanting to stay ahead of the curve on Wall Street.Don't forget to like, comment, and subscribe for more in-depth market analysis and actionable insights!#MarketMoves #PrescriptionDrugs #HealthcareStocks #TrumpNews #Amazon #AMD #TechStocks #AI #Investing #StockMarket #Finance #BusinessNews #MarkCuban #Pharma #EliLilly #Pfizer #JohnsonAndJohnson #Pharmaceuticals #Innovation #BusinessAnalysis #AmazonPrime #WallStreet #FinancialNewsSupport this podcast at — https://redcircle.com/marketmondays/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Tenemos en esta ocasión un capítulo especial. Nos adentramos en la historia de la diabetes, una enfermedad que pasó de ser un misterio en la antigüedad a convertirse en un reto global en el siglo XXI. Comprenderla es vital para todos, no solo por su impacto en millones de personas, sino porque revela cómo nuestros hábitos, la alimentación y situaciones sociales influyen directamente en nuestra salud y la de las personas que nos rodean. Conocer la diabetes es entender cómo vivimos y qué podemos cambiar para cuidarnos mejor. Notas del episodio: Este episodio fue patrocinado por Eli Lilly, A Medicine Company El origen de la palabra diabetes Historia de la diabetes El descubrimiento de la insulina Herramientas para conocer tu riesgo de Diabetes Datos de la ONU sobre las diabetes Y aquí les dejamos la página de la Asociación Colombiana de Diabetes  ¡Síguenos en nuestras redes sociales! Facebook: / dianauribe.fm Instagram: https://www.instagram.com/dianauribe.fm/ T witter: https://twitter.com/dianauribe.fm?lang=es Pagina web: https://www.dianauribe.fm TikTok: https://www.tiktok.com/@dianauribe.fm?is_from_webapp=1&sender_device=pc LinkedIn: https://www.linkedin.com/in/diana-uribe-/?originalSubdomain=co  

Cramer breaks down why he ‘likes' this pharmaceutical stock. Become a CNBC Investing Club member to go behind the scenes with Jim Cramer and Jeff Marks as they talk candidly about the market's biggest headlines. Signup here: cnbc.com/morningtake CNBC Investing Club Disclaimer

In this podcast episode, Ryan Stidham, MD, discusses the evolution and development of digital imaging and AI in the GI space, how AI can revolutionize stages within the clinical trials and practices and more. •    Intro :24 •    The interview/about Stidham :36 •    Tell us about your family and where you grew up. 1:14 •    How did you embrace changes in technology growing up? 3:07 •    What was the seminal moment that got you to move from being a consumer of information to being a producer and innovator?  6:05 •    What ignited you to start commercializing and patenting your ideas, and operationalizing them into a company? How did that evolution occur? 8:32 •    Can you give a quick overview of what these tools and technologies entail?  12:52 •    What got you interested in inflammatory bowel disease, and how did your childhood interest in coding shift to artificial intelligence? 18:12 •    Where did your interest in AI come about? 20:26 •    You recently published a review on how AI will revolutionize the conduct of clinical trials in inflammatory bowel disease […] Will AI remove the need for central reading in IBD trials in the future? 23:58 •    How do we change the way we train GI doctors, and should we start making these changes today? 26:38 •    With AI rapidly changing the landscape, are we spending enough time educating our fellows in how to adapt to changes and communicate with patients? 32:33 •    What do you think will change in IBD and gastroenterology in the near term as a result of AI? 35:06 •    What is it that we really need in terms of health care access, and how can AI technology assist these needs? 38:39 •    Thank you, Ryan 44:04 •    Thanks for listening 44:20 Ryan Stidham, MD, MS, AGAF, is a translational scientist caring exclusively for patients with inflammatory bowel disease. He is an associate professor in the department of medicine and the department of computational medicine and bioinformatics where he serves as the associate chair of translational research. His research focus is the use of artificial intelligence to improving measurement of IBD and other gastrointestinal diseases, developing new interpretations of cross-sectional imaging, endoscopy, medical text, and other electronic data.  We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more from Stidham, follow @CrohnsDoc on X. Disclosures: Berry and Chey report no relevant financial disclosures. Stidham reports consulting or on advisory boards for AbbVie, Bristol Myers Squibb, CorEvitas, Eli Lilly, Exact Sciences, Gilead, Janssen, Merck, Pfizer, and Takeda. Stidham holds intellectual property and equity on medical imaging and endoscopic analysis technologies licensed by the University of Michigan to PreNovo, LLC, AMI, LLC and PathwaysGI, Inc.

Synopsis: What does bold biotech leadership look like in 2025? In this episode of Biotech 2050, host Alok Tayi sits down with Stacy Lindborg, President & CEO of Imunon, to discuss bold innovation in ovarian cancer treatment and how harnessing the immune system through targeted gene therapy is reshaping survival outcomes. Stacy shares insights from her 30-year career—from her statistical roots at Eli Lilly to her mission-driven leadership at Imunon. She highlights the groundbreaking results from Imunon's IL-12 plasmid platform, which is showing a remarkable 13-month overall survival advantage in ovarian cancer patients and is now entering Phase 3 trials. They also discuss the evolving biotech landscape, how adaptive trial designs and AI are unlocking clinical potential, and why cultivating a bold, transparent company culture is key to advancing transformational science. Biography: Stacy R. Lindborg, PhD, was appointed President and Chief Executive Officer of Imunon in May 2024. Dr. Lindborg has served on Imunon's Board of Directors since June 2021. Dr. Lindborg has nearly 30 years of pharmaceutical and biotech industry experience with a particular focus on R&D, regulatory affairs, executive management and strategy development. She has designed, hired and led global teams, guiding long-term vision for growth through analytics and stimulating innovative development platforms to increase productivity. Prior to joining Imunon, Dr. Lindborg was Executive Vice President and Co-Chief Executive Officer at BrainStorm Cell Therapeutics where she will remain a member of the company's Board of Directors. At BrainStorm she was accountable for creating and executing clinical development strategies through registration and launch and progressed its novel cell therapy for ALS through a positive Phase 3 Special Protocol Assessment (SPA) study with the U.S. Food and Drug Administration. She interacted frequently with investors and analysts, represented the company in the scientific community as well as with the media, and played an active role in discussions with potential business partners. Dr. Lindborg previously was Vice President & Global Analytics and Data Sciences Head, responsible for R&D and marketed products at Biogen. She began her biopharmaceutical career at Eli Lilly and Company where over the course of 16 years she assumed positions of increasing responsibility, including Head of R&D strategy. Dr. Lindborg received an M.A. and Ph.D. in statistics, and a B.A. in psychology and math from Baylor University. She has authored more than 200 presentations and 90 manuscripts that have been published in peer-reviewed journals, including 20 first-authored. She has held numerous positions within the International Biometric Society and American Statistical Association and was elected Fellow in 2008.

This Oncology PER®Spectives™ podcast explores the role of EZH2 in metastatic castration-resistant prostate cancer (mCRPC) progression and its synergy with androgen receptor inhibitors. In this podcast, experts Neeraj Agarwal, MD, FASCO; Himisha Beltran, MD; and Maha Hussain, MD, FACP, FASCO, discuss the management of mCRPC. Acknowledgment of Educational Grant Support This activity is supported by an educational grant from Pfizer Inc. Accreditation/Credit Designation Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours. Instructions on How to Receive Credit Listen to this podcast in its entirety. Go to gotoper.com/credit and enter code: 6947 Answer the evaluation questions. Request credit using the drop-down menu. You may immediately download your certificate. Today's faculty are: Neeraj Agarwal, MD, FASCO Professor of Medicine Senior Director for Clinical Research HCI Presidential Endowed Chair of Cancer Research Director, Center of Investigational Therapeutics Director, Genitourinary Oncology Program Huntsman Cancer Institute, University of Utah (NCI-CCC) Salt Lake City, UT Disclosures: Grant/Research Support (paid to institution): Arvinas, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, GlaxoSmithKline, Immunomedics, Janssen, Lava, Merck, Nektar, Neoleukin, Novartis, Oric, Pfizer, Roche, Sanofi, Seagen, Takeda, Tra-con Himisha Beltran, MD Associate Professor of Medicine Director of Translational Research Within Medical Oncology Harvard Medical School Lank Center for Genitourinary Oncology and the Division of Molecular and Cellular Oncology Dana Farber Cancer Institute Boston, MA Disclosures: Grant/Research Support: Circle Pharma, Daiichi Sankyo, Novartis; Adviser: Amgen, AstraZeneca, Daiichi Sankyo, Novartis Maha Hussain, MD, FACP, FASCO Genevieve E. Teuton Professor of Medicine Professor, Medicine (Hematology/Oncology) Deputy Director Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine Chicago, IL Disclosures: Advisory Board: AstraZeneca, Bayer, Convergent Therapeutics, Honoraria: AstraZeneca, Bayer The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with ineligible companies. PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process. Off-Label Disclosure and Disclaimer This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity. Release Date May 14, 2025 Expiration Date May 14, 2026

This 4-in-1 compilation episode focuses on a persistent disconnect between capital and capability: women are founding businesses at record rates and leading high-performing funds, yet the capital rarely follows.In other words, women are underrepresented both in receiving and managing capital.Today's episode is about those pushing back against that trend – women-led investment managers and those intentionally channeling capital into women-led businesses.Here are the featured guests:Sharon Vosmek, CEO of Astia & Managing Partner of the Astia FundSharon Vosmek doesn't see gender equity in venture as a social goal – she sees it as a market inefficiency. With just 2–3% of VC funding going to women CEOs, she argues the system consistently overlooks high-potential founders. At Astia, she's investing in women-led startups with strong early traction, particularly in underserved sectors like women's health. She also challenges the informal, male-dominated networks – boardrooms, golf courses – where most deals are still made.Full episode Dr. Tara Bishop, Founder and Managing Director of Black Opal VenturesTara co-founded Black Opal Ventures to invest where healthcare and technology collide – and where traditional VC often misses.She and her partner, Eileen Tanghal, raised $63 million from institutional investors like Eli Lilly and JP Morgan, becoming one of the rare female- and minority-led funds in venture. Their portfolio reflects that identity: women-led companies, underserved markets, and problems overlooked by legacy capital.Full episode Tammy Newmark, CEO and Managing Partner of EcoEnterprises FundTammy leads EcoEnterprises Fund, a women-run investment firm focused on nature-positive businesses across Latin America. For over two decades, she's backed companies in sustainable agriculture, ecotourism, and agroforestry – many led by women and rooted in rural or Indigenous communities.Gender equity isn't the fund's focus, but it runs through the portfolio: in leadership teams, supply chains, and daily operations. About half of their investments meet 2X Challenge criteria – not because it's the mandate, but because that's who's doing the work.With $150 million under management, the fund combines financial discipline with long-term environmental and social goals.Full episode Stephanie Cohn Rupp, CEO of Veris Wealth PartnersStephanie runs Veris Wealth Partners, one of the few wealth management firms built from the ground up to do just one thing: impact. With $2.3 billion under management and offices across the U.S., Veris has been majority women-led and women-owned since its founding in 2007.It's built entirely around impact – certified B Corp, net zero, and intentionally conflict-free – and applies that lens across every asset class, with a deep focus on racial equity, climate, gender, and community wealth.For Stephanie, this isn't about doing impact. It's about being built for it.Full episode—The SRI 360° Podcast is focused exclusively on sustainable & responsible investing.—Connect with SRI360°:Sign up for the free weekly email update.Visit the SRI360° PODCAST.Visit the SRI360° WEBSITE.Follow SRI360° on X.Follow SRI360° on FACEBOOK.

Kenzie details the complex murder of an Eli Lilly employee. Chicago’s best morning radio show now has a podcast! Don’t forget to rate, review, and subscribe wherever you listen to podcasts and remember that the conversation always lives on the Q101 Facebook page. Brian & Kenzie are live every morning from 6a-10a on Q101. Subscribe to our channel HERE: https://www.youtube.com/@Q101 Like Q101 on Facebook HERE: https://www.facebook.com/q101chicago Follow Q101 on Twitter HERE: https://twitter.com/Q101Chicago Follow Q101 on Instagram HERE: https://www.instagram.com/q101chicago/?hl=en Follow Q101 on TikTok HERE: https://www.tiktok.com/@q101chicago?lang=enSee omnystudio.com/listener for privacy information.

The Indiana Pacers are one game away from advancing to the NBA Eastern Conference Finals. Eli Lilly and Company announce an expanded partnership with Purdue University. An Indianapolis Public Schools district school will convert to a charter school. The Trump Administration terminates federal funding that supports artists across Indiana. Want to go deeper on the stories you hear on WFYI News Now? Visit wfyi.org/news and follow us on social media to get comprehensive analysis and local news daily. Subscribe to WFYI News Now wherever you get your podcasts. WFYI News Now is produced by Drew Daudelin, Zach Bundy and Abriana Herron, with support from News Director Sarah Neal-Estes.

Progress continues to...progress on the Eli Lilly site on the north side of town. On Episode 212 of the #LovinLebanon Podcast, we check in with Todd Dando and Jeff Wagner from Fluor Corporation to get an update on the construction process. Roughly two thousand workers are on-site right now, but that number is about to increase. Jeff and Todd share the efforts in place to meet upcoming challenges.

Networking is an integral part of our lives, both professional and personal.  I welcome back Nancie McDonnell Ruder, an extraordinary business woman from the Warrior community, to discuss the skills of networking and connecting with others.  We discuss how we can cultivate the best mindset and what tactical tips, inspiration and perspectives can we learn that will help us to connect and network better.  Nancie McDonnell Ruder is an executive coach, leadership advisor and marketing consultant with decades of experience in marketing strategy, training, branding, and consumer research. She has a strong track record of driving accelerated growth for organizations by aligning their marketing strategies closely with customer expectations and preferences.  Nancie began her professional career with the Leo Burnett Company in Chicago, Illinois, where she served clients such as Procter & Gamble, Eli Lilly and The Gap, and spearheaded global new business efforts, resulting in 14 cross market new business wins.  Since launching Noetic Consultants in 2002, Nancie has provided strategic guidance to clients large and small, including: 7-Eleven, Discovery Channel, Georgetown University, NIKE, Vail Resorts, Samsung Electronics, SC Johnson, Mayo Clinic, and the Walt Disney Company. She is the creator of the Noetic Brand Health Diagnostic™ and the Noetic Art & Science Assessment™.  In addition to her consulting work, Nancie is a respected author and sought-after speaker in the marketing and leadership space. Her engaging presentations draw from her extensive experience, providing actionable takeaways that help organizations and individuals thrive in today's competitive business landscape.(3:42)  Why did we decide to partner and discuss networking?  (6:05) The word “networking”, how do we define it?  (12:40) How can we integrate networking into our personal and professional lives?  (14:37) Why networking matters? What are some of the barriers we experience related to networking?  (18:32) What are some of the fears we experience when we don't exercise our “networking muscles” regularly?  (20:55) Nancie discusses the many ways we can use networking in our lives.  (23:05) We talk about the concept of “Give and Take” from Adam Grant.  (28:30) We discuss concepts of “helping others to succeed first”, how we are “you're only as good as your network” and “you can't get there alone and you don't want to”.  (32:20) Thinking of interactions with others as an “ask, offer and acknowledge”.  (35:54) Where can someone begin on the path to successful networking?  How can we learn good habits from the beginning?  (45:08) Tactical things you can do before networking with others.  (48:26) Do's and Don'ts when networking  (55:25) Let's wrap up the highlights of our conversation around being connected and networking.  (56:47) We ask the community to take away an important point from our conversation.Connect with Nancie McDonnell Ruder https://www.linkedin.com/in/nancieatnoetic/ https://noetic.io/   Subscribe: Warriors At Work Podcasts Website: https://jeaniecoomber.com Facebook: https://www.facebook.com/groups/986666321719033/ Instagram: https://www.instagram.com/jeanie_coomber/ Twitter: https://twitter.com/jeanie_coomber LinkedIn: https://www.linkedin.com/in/jeanie-coomber-90973b4/ YouTube: https://www.youtube.com/channel/UCbMZ2HyNNyPoeCSqKClBC_w

In this episode, Scott Becker discusses sharp market declines for Coca-Cola, Eli Lilly, and Becton Dickinson.

Scott Wapner and the Investment Committee debate the rebound in stocks as the S&P 500 heads for its longest winning streak in 20 years. The experts detail their latest portfolio moves. CNBC Senior Markets Commentator Michael Santoli joins from Omaha with a special Midday Word ahead of Berkshire Hathaway's annual shareholder meeting. Calls of the Day include AutoZone, Roblox, Eli Lilly, Johnson & Johnson, and Quanta Services. NBC Sports host Mike Tirico is live in Churchill Downs ahead of the 151st Kentucky Derby. The Setup is on Ferrari, Zoetis, Elanco Animal Health.Investment Committee Disclosures

Earnings season is in full swing, with Apple and Amazon headlining the action. Deepwater Asset Management's Gene Munster joins to break down the key takeaways from the day's big reports. And Eli Lilly dropping as the drugmaker cuts its profit forecast. Mizuho's Jared Holz digs into the details, and where the pharma space is heading next. Plus, how the markets are setting up ahead of tomorrow's jobs report.  Fast Money Disclaimer

Carl Quintanilla, Jim Cramer and David Faber discussed blowout quarterly results from Microsoft and Meta that sparked a rally inthe tech sector -- as the Dow and S&P 500 aim to extend their respective daily win streaks to eight. The anchors also reacted to Tesla's denial of a report stating the company's board opened a search for a successor to CEO Elon Musk. Also in focus: Eli Lilly and McDonald's join the earnings parade, Softbank CEO Masa Son on China and AI, President Trump's "two dolls" comment on tariffs.

Scott Wapner and the Investment Committee debate where the economy is heading as tariff turmoil sends GDP into the red. The panel take their position on big tech ahead of earnings. Karen Firestone details her latest portfolio moves. Calls of the Day include AppLovin, CoStar, Cheniere, Spotify, and Raymond James. The earnings setup is on Allstate, Eli Lilly, Amgen, Live Nation, and Exxon Mobil. 

Scott Wapner and the Investment Committee discuss whether stocks are poised for a major comeback as we mark the first 100 days for President Trump. Bill Baruch calls in with reaction to Spotify. Josh Brown details his latest portfolio moves. The panel debates the red-hot cyber trade. The Setup is on Eli Lilly and Shake Shack.Investment Committee Disclosures

Want the skinny on the magic pill everyone is talking about? If you've ever considered trying Ozempic or a similar weight loss drug, you're not alone! In this episode, I share the pros and cons of Ozempic, my honest and objective perspective, and my top weight loss tips.The hard truth is that weight loss is difficult! With Eli Lilly's announcement of a phase 3 trial for a cheaper, oral weight loss pill, this topic is hotter than ever. One thing to consider is that a quick fix pill doesn't make you healthier or ensure the weight stays off, whereas doing strength and nutrition work guarantees a healthier tomorrow. When we get down to it, it's not the weight loss itself that's hard, it's the behavior modification that supports a healthy lifestyle that some people struggle with. I share my analysis of the Ozempic results, and the conclusion will surprise you! In particular, the reasons why you are better off without taking a weight loss drug and instead joining my program, the Body Composition Project, where participants lose double their body weight in half the time of what Ozempic clinical trials report. Crazy, right?! I then explain why a mindset shift is essential to long-lasting weight loss, how to improve your insulin sensitivity, and the importance of building muscle to lose fat. Remember, you have the power to change your body composition today. Why wait!Ready for a great night's sleep? Try Beam's best-selling Dream Powder and get up to 40% off for a limited time. Visit shopbeam.com/HOLLYP and use code HOLLYP at checkout.You can get FREE access to my 4-week Strength Without Stress program right now! Thisprogram will help you reduce the systemic inflammation that's caused by overly intense orlengthy workouts. It'll help you build and maintain valuable lean muscle withoutthe fatigue from other programsTo get free access to Strength Without Stress, post a Review wherever you listen. Grab a screenshot of your review before you post it and upload at: https://www.hollyperkins.com/reviewThis is a limited-time offer before it sells for $197–grab it while you can for lifetime access.Be sure to Follow and Subscribe so you'll know exactly when new episodes are available on Tuesdays.Topics coveredThe temptation of effortless weight lossWeight loss IS hard! Weight loss medications work, but at what cost?Why behavior modification is so challengingThree key misunderstandings about weight loss drugsReasons why you're better off without weight loss medicationWhy a mindset shift is key to sustainable weight lossRemember, not eating causes weight loss AND muscle lossResources MentionedResearch on Eli Lilly's oral weight-loss pill shows promising resultsResearch on healthy weight loss maintenanceResearch about understanding a diabetes diagnosisResearch about the effect of semaglutide on overweight adultsResearch summary on the impact of semaglutide on obese adultsResearch on resistance

Why did news from a weight-loss drug pill trial boost Eli Lilly? And how are costs in the Medicare business affecting UnitedHealth? Plus, what ambitious goals has Netflix set for itself? Host Francesca Fontana discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Tesla class action lawsuit… Google guilty… Meta is still under fire… Menendez hearing in May… Administration lawsuits abounding… Supreme Court will look at birthright… Message in a Bottle found… NBA / NHL playoffs begin… Lee Corso retiring… Mike Leach talked down from idea… Email: ChewingTheFat@theblaze.com Swimming with Aqua Tots… Who Died Today: Patrick Adiarte 82… Puerto Rico loses power and water… Eli Lilly moving forward with anti-fat pill… Pfizer cancels anti-fat pill?... Seed Oils and Breast Cancer… www.blazetv.com/jeffy Promo code Jeffy… Game Show: What's The Lie? Contestant: Dakota Lally / returning champion… Learn more about your ad choices. Visit megaphone.fm/adchoices